Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALKBH5 | Q6P6C2 | 17/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8751526 | 0.85 | ALKBH5 (0.56) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL10390963 | 0.83 | ALKBH5 (0.56) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL67421 | 0.80 | ALKBH5 (0.66) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL10900934 | 0.80 | ALKBH5 (0.58) | ALKBH5KDM4EALDH1A1MAPT | |
| SCHEMBL1939982 | 0.78 | ALKBH5 (0.46) | ALKBH5KDM4EALDH1A1 | |
| SCHEMBL693607 | 0.78 | ALKBH5 (0.48) | ALKBH5 | |
| SCHEMBL10413159 | 0.78 | ALKBH5 (0.50) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL10412743 | 0.78 | ALKBH5 (0.50) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL10412044 | 0.78 | ALKBH5 (0.47) | ALKBH5KDM4EALDH1A1MAPTKMT2A | |
| SCHEMBL8076096 | 0.77 | ALKBH5 (0.45) | ALKBH5KDM4EALDH1A1MAPTTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421501-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND USE THEREOF | The Procter & Gamble Company (US) | 2012-02-29 | — | — | EP | claimed |
| US-7988740-B2 | Keratin dyeing compositions comprising a radical scavenger and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-02 | — | — | US | claimed |
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | NOXELL CORPORATION | 2011-02-17 | — | — | US | claimed |
| WO-2010123863-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2010-10-28 | — | — | WO | claimed |
| EP-2421501-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND USE THEREOF | The Procter & Gamble Company (US) | 2012-02-29 | — | — | EP | disclosed |
| US-7988740-B2 | Keratin dyeing compositions comprising a radical scavenger and use thereof | THE PROCTER & GAMBLE COMPANY (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | NOXELL CORPORATION | 2011-02-17 | — | — | US | disclosed |
| WO-2010123863-A2 | KERATIN DYEING COMPOSITIONS COMPRISING A RADICAL SCAVENGER AND USE THEREOF | THE PROCTER & GAMBLE COMPANY (US) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110035885-A1 | Keratin Dyeing Compositions Comprising a Radical Scavenger and Use Thereof | KRT18, LPO, CYB5R3 | ALKBH5 413/4885KDM4E 841/4885ALDH1A1 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.